VivoSeq
Cardiovascular

Cardiac Edema

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Cardiac Edema is an early-stage landscape with 3 programs across 2 companies. The most active players are Otsuka, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema
Not yet recruiting·JJemincare·Phase 2·NCT06949020·160 enrolled
Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema
Completed·Otsuka logoOtsuka·Phase 3·NCT01651156·244 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)